Thailand’s first National Biopharmaceutical Facility officially opens

24 March 2014, Bangkhunthien - H.R.H. Princess Maha Chakri Sirindhorn presided over the opening ceremony of National Biopharmaceutical Facility (NBF) located at King Mongkut’s University of Technology Thonburi (KMUTT), Bangkhunthien Campus. It is Thailand’s first state-owned contract manufacturing facility for the production of clinical, research-grade biopharmaceuticals.

DSC 2710

NBF was initiated in 2008 under the collaboration between BIOTEC/NSTDA and KMUTT. The facility consists of 2 production suites for microbial fermentation and cell culture with corresponding downstream processing capabilities and an automatic sterile fill and finish line, which were all designed to comply with international GMP standards and biosafety regulations. NBF has also acquired a license from Thai FDA to manufacture drug, vaccine and biologics.


As part of the national vaccine plan, NSTDA is currently coordinating the dengue vaccine development endeavor, focusing on three approaches namely chimeric live-attenuated vaccine, DNA vaccine and VLP vaccine;  whereas BIOTEC is now working on animal vaccine and the up-stream technology such as the development of recombinant host cell and expression system.

For more information about National Biopharmaceutical Facility (NBF), please visit

Posted on 26 March 2014